LITESPARK-012: Pembrolizumab Plus Lenvatinib With or Without Belzutifan or Quavonlimab for Advanced Renal Cell Carcinoma
Year: 2023
Type: article
Study design: Study Protocol
Abstract: Combination treatment with immunotherapy agents and/or vascular endothelial growth factor tyrosine kinase inhibitors are a standard of care for patients with advanced clear cell renal cell carcinoma (ccRCC). Novel therapeutic combinations that include the hypoxia-inducible factor 2α inhibitor belzutifan and the cytotoxic T-lymphocyte–associated protein 4 inhibitor quavonlimab are being investigated for their potential to further improve patient outcomes. This protocol describes the rationale and design of the randomized, phase III LITESPARK-012 study, which will evaluate the efficacy and safety of pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab as first-line treatment for advanced ccRCC. Results from this study may support triplet combination therapies as a potential new standard of care for advanced ccRCC. Clinical trial registry: NCT04736706 (ClinicalTrials.gov)
Source: Future Oncology
Institutions: Harvard University, Dana-Farber Cancer Institute, Queen Mary University of London, Barts Health NHS Trust, The Royal Free Hospital, Barts Cancer Institute, Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center, Westmead Hospital, Macquarie University, Merck & Co., Inc., Rahway, NJ, USA (United States), Vanderbilt University, Vanderbilt-Ingram Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4387949844